New hope for transplant patients fighting rejection when steroids fail

NCT ID NCT06462469

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing the drug ruxolitinib in Chinese adolescents and adults who have developed a severe immune reaction (acute graft-versus-host disease) after a stem cell transplant and have not responded to standard steroid treatment. The goal is to see if ruxolitinib can control this dangerous complication and reduce the need for steroids. Researchers will monitor 36 participants for one year to measure how well the drug works and how safe it is.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430030, China
Novartis Investigative Site
RECRUITING

Changchun, Jilin, 130021, China
Novartis Investigative Site
RECRUITING

Xian, Shanxi, 710061, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610072, China
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
RECRUITING

Beijing, 100028, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100039, China
Novartis Investigative Site
RECRUITING

Beijing, 100070, China
Novartis Investigative Site
RECRUITING

Dalian, 116000, China
Novartis Investigative Site
RECRUITING

Fuzhou, 350001, China
Novartis Investigative Site
RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Taian, 271099, China
Novartis Investigative Site
RECRUITING

Tianjin, 300020, China

Conditions

Explore the condition pages connected to this study.

STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE